PML and MDM2

  • Number of citations of the paper that reports this interaction (PMID 15195100)
  • 79
  • Data Source:
  • BioGRID (affinity chromatography technology, affinity chromatography technology, affinity chromatography technology)
  • HPRD (in vivo, in vitro)

PML

MDM2

Gene Name promyelocytic leukemia MDM2 proto-oncogene, E3 ubiquitin protein ligase
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9 185 interactors: ABL1 ADRB2 ADRBK1 AKT1 ANKRD17 APEX1 APP AR ARRB2 ATF3 ATF4 ATM ATP2A2 AURKA BAIAP2L1 BRINP1 BTRC CANX CASP2 CASP3 CCAR1 CCNG1 CDH1 CDKN2A CHEK2 CLSTN1 CLU COPS5 CREBBP CTBP2 CWC25 DAPK1 DAPK3 DAXX DHFR DLG4 DNAJB4 DYRK2 E2F1 EID1 EP300 ESR1 EZR FOXO1 G3BP2 GADD45A GCAT GLTSCR2 GNL3 GORAB GSK3B GTF2E1 GTF2E2 HDAC1 HIF1A HIPK2 HIST2H2BE HIST3H3 HLA-DMB HRSP12 HSP90B1 IGF1R IRF1 IRF2 JMY JUN JUND KAT2B KAT5 LMO7 MDM4 MED1 MKRN3 MS4A1 MTBP MYD88 MYDGF NACA NCL NOTCH1 NPM1 NR3C1 NUMB PAK6 PBX1 PDE4D PDIA3 PDLIM7 PGAM2 PHF7 PIAS1 PJA1 PKM PLK1 PML POLE POT1 PPIB PPM1D PSMA3 PSMC5 PSMD10 PSMD4 PSME3 PTK2 RAB8A RABL6 RAD23A RANBP1 RANBP2 RASSF1 RB1 RBM38 RCHY1 RNF10 RNF126 RNF8 RPL11 RPL26 RPL5 RPS23 RPS27A RPS3 RPS7 RRM2B RUVBL2 RYBP RYR2 S100A1 S100A2 S100A4 S100A6 S100B SDHC SENP3 SESN2 SET SETDB1 SHPK SMARCA2 SMARCA4 SMARCE1 SORBS2 SREK1 SRSF11 SUMO1 TAF1 TBP TCAP TERT TOP1 TP53 TP73 TPR TPT1 TRAF5 TRIM23 TRIM27 TRIM4 TRIM9 TSC22D3 TSG101 UBB UBE2A UBE2D1 UBE2D2 UBE2D3 UBE2E2 UBE2E3 UBE2G2 UBE2I UBE2K UBE2L3 UBE2M UBE2U UBE2Z UBE3A UBQLN4 UBTF USP2 USP7 WT1 XPC YY1AP1 ZNF133
Entrez ID 5371 4193
HPRD ID 00023 01272
Ensembl ID ENSG00000140464 ENSG00000135679
Uniprot IDs P29590 A7UKX7 A7UKX8 A7UKX9 G3XA89 Q00987 Q96DS0
PDB IDs 1BOR 1RV1 1T4E 1T4F 1YCR 1Z1M 2AXI 2C6A 2C6B 2F1Y 2FOP 2GV2 2HDP 2LZG 2M86 2VJE 2VJF 3EQS 3G03 3IUX 3IWY 3JZK 3JZR 3JZS 3LBK 3LBL 3LNJ 3LNZ 3TJ2 3TPX 3TU1 3V3B 3VBG 3VZV 3W69 4DIJ 4ERE 4ERF 4HBM 4HFZ 4JV7 4JV9 4JVE 4JVR 4JWR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
abundance  bound  cbp  coactivator  destabilizer  directed  e1a  endogenous  h1  implies  implying  interactions  intimately  naturally  normally  occurring  operate  overproducing  p300  p53  regard  serves  stability  stabilizing  steps  taken  translates  turnover  underscored 
Tagcloud (Difference) ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
abundance  bound  cbp  coactivator  destabilizer  directed  e1a  endogenous  h1  implies  implying  interactions  intimately  naturally  normally  occurring  operate  overproducing  p300  p53  regard  serves  stability  stabilizing  steps  taken  translates  turnover  underscored 
Tagcloud (Intersection) ?